ArticleGenomics, proteomics & bioinformatics2025
Macrophage Response to Avirulent and Virulent Mycobacterium tuberculosis and Anti-TB Effects of Exosome Treatment.
Article in Genomics, proteomics & bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) has returned as the leading cause of death caused by a single infectious agent in 2023. Human macrophages and their secreted exosomes play important roles in combating invading Mycobacterium tuberculosis (Mtb). However, a comprehensive understanding of the mechanisms underlying immune regulation in Mtb-infected macrophages, as well as the packaging mechanisms and anti-TB effects of Mtb-treated exosomes, is still lacking. Here, we conducted comprehensive analyses of the macrophages infected with avirulent and virulent Mtb strains (H37Ra and H37Rv) and their exosomes through omics and phenotypic approaches. The results showed that H37Ra stimulated strong immune responses and apoptosis in macrophages to eliminate invading Mtb, while H37Rv induced severe necrosis and immune escape for survival. Interestingly, our results suggest that macrophages kill Mtb in an interferon-gamma (IFN-γ)-independent but compensatory way, highlighting the central role of IFN signaling pathway in anti-TB response. Moreover, we observed selective transport of host and Mtb RNAs from macrophages to exosomes. Notably, H37Ra-treated exosomes displayed a higher anti-TB effect than H37Rv-treated exosomes due to some enriched pro-inflammatory and immune escape-related Mtb proteins in these two exosomes, respectively. In conclusion, our findings shed new light on the immune mechanisms of macrophages in response to Mtb infection, offering a new TB treatment strategy and promising vaccine candidates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.